Under Construction!

About me

Living the Life of Reily in Grass Lake

I've lived on the east coast, south east and midwest.  After high school, I was a professional cook for a year before heading off to college to study chemistry.  Got a batchelors degree from the University of West Florida and a Ph.D. from Emory University.  After a post-doc at the University of Wisconsin, I started my 32 year career as an analytical chemist at Parke-Davis (which became Pfizer) in Ann Arbor, MI and finished it at Bristol-Myers Squibb in Princeton, NJ.  I thoroughly enjoyed doing science at these companies, but at this stage of life, retirement is where it's at!

Bibliography

 

 

PATENTS

 

  1. Reily MD, Robosky LC, Wade KJ.  Assay of sebum lipid components by nuclear magnetic resonance.    PCT Int. Appl.  (2006),     34pp.  WO  2006095238

 

Publications

 

Book Chapters

 

  1. Reily M.D., and Xu Q. (2017) NMR Spectroscopy in the Evaluation of Drug Safety. In: Lindon, J.C., Tranter, G.E., and Koppenaal, D.W. (eds.) The Encyclopedia of Spectroscopy and Spectrometry, 3rd edition vol. 3, pp. 232-238. Oxford: Academic Press.
  2. Drexler, D.M., Olah, T.V., Reily, M.D., Shipkova, P.A., Soares, H.D., Tymiak, A.A. Bioanalysis of biomarkers in support of drug discovery and development (2014) Eliminating Bottlenecks for Efficient Bioanalysis: Practices and Applications in Drug Discovery and Development, pp. 182-199.

 

  1. Aranibar N, Reily MD, NMR methods for metabolomics of mammalian cell culture bioreactors (2014) In: Pörtner R. (ed) Animal Cell Biotechnology. Methods in Molecular Biology (Methods and Protocols), vol 1104. Humana Press, Totowa, NJ, pp. 223-236.
  2. Shipkova P, Reily MD. Mass Spectrometry for Metabolomics (2013) Mass Spectrometry for Drug Discovery and Drug Development, pp. 387-401. Ed: Walter A. Korfmacher.  John Wiley and Sons, Inc.  Published Online: 17 January 2013 DOI: 10.1002/9781118516157.ch14

 

  1. Reily MD, Huang S, Caceres-Cortes J, Johnson K, Shu Y-Z. Nuclear Magnetic Resonance Spectroscopy for the Study of Drug Metabolism (2012) Encyclopedia of Drug Metabolism and Interactions, volume IX: Bioanalytical Methods of Studying Metabolism, John Wiley and Sons, Inc., ed: Alexander Lyubimov, published online January 31, 2012. http://dx.doi.org/10.1002/9780470921920.edm102

 

  1. Jackson J, Townsend R, Reily M, Soares H, Averbuch S.  “Scientific Domains of Personalized Medicine” (2011) Personalized Medicine: Prescriptions and Prospects, Food and Drug Law Institute, Washington, D.C., eds: Hawana J and Runkle D, Ch 1, 1-15.

 

  1. Reily MD, Shipkova P, Hnatyshyn SH. LC-MS in Endogenous Metabolite Profiling and Small Molecule Biomarker Discovery (2011) Mass Spectrometry in Drug Metabolism and Disposition:  Basic Principles and Applications, John Wiley and Sons, Inc., eds: Lee M, Zhu M, Ch 21, 685-722.

 

  1. Robertson DG, Reily MD, Cantor GH.  Metabonomics in Preclinical Pharmaceutical Discovery and Development (2007) The Handbook of Metabonomics and Metabolomics, eds: Lindon LC, Nicholson, JK, Holmes, E,
    Elsevier Science BV
    , 241-276.

 

  1. Reily MD, Lindon JC. NMR Spectroscopy: Principles and Instrumentation (2005) Metabonomics in Toxicity Assessment, eds: Robertson DG and Lindon JC, CRC press, 75-104.  Publisher: Taylor & Francis,  Boca Raton, FL.

 

  1. Robertson DG, Reily MD, Lindon JC, Holmes E, Nicholson JN. Metabonomic technology as a tool for rapid throughput In Vivo toxicity screening (2002) Comprehensive Toxicology V14, eds: Vanden Heuvel JP, Perdew GH, Mattes WB, Greenlee WF, Elsevier Science BV.

 

  1. Reily MD, Bokman AB, Offord J, McConnell P, NMR Spectroscopy of peptide ion channel ligands:  cloning and expression as an aid to the evaluation of structural and dynamic properties. (1998) Methods in Enzymology V294, ed: Conn PM, Academic Press.

 

Journal Articles

 

  1. Tian, J., He, Q., Oliveira, C., Qian, Y., Egan, S., Xu, J., Qian, N.-X., Langsdorf, E., Warrack, B., Aranibar, N., Reily, M., Borys, M., Li, Z.J.  Increased MSX level improves biological productivity and production stability in multiple recombinant GS CHO cell lines (2020) Engineering in Life Sciences, in the press.

 

  1. Khandelwal, P., Zhang, L., Chimalakonda, A., Caceres-Cortes, J., Huang, C., Marathe, P., Reily, M.D. Pharmacokinetics of 40 kDa PEG in rodents using high-field NMR spectroscopy (2019) Journal of Pharmaceutical and Biomedical Analysis, 171, pp. 30-34.

 

  1. Liu, J., Curtin, J., You, D., Hillerman, S., Li-Wang, B., Eraslan, R., Xie, J., Swanson, J., Ho, C.-P., Oppenheimer, S., Warrack, B.M., McNaney, C.A., Nelson, D.M., Blum, J., Kim, T., Fereshteh, M., Reily, M., Shipkova, P., Murtaza, A., Sanjuan, M., Hunt, J.T., Salter-Cid, L. Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance (2019) PLoS ONE, 14 (3), art. no. e0212670

 

  1. Shen H, Nelson DM, Oliveira RV, Zhang Y, McNaney CA, Gu, X, Chen W, Su C, Reily MD, Shipkova PA, Gan J, Lai Y, Marathe P, Humphreys WG, Discovery and validation of pyridoxic acid and homovanillic acid as novel endogenous plasma biomarkers of organic anion transporter (OAT) 1 and OAT3 in Cynomolgus monkeys (2018) Drug Metabolism and Disposition, 46 (2), pp. 178-188.

 

  1. Drexler DM, McNaney CA, Wang Y, Huang X, Reily MD, The utility of qNMR to improve accuracy and precision of LC-MS bioanalysis (2018) Journal of Applied Bioanalysis, 4 (1), 26-31.

 

  1. Harner MJ, Mueller L, Robbins KJ, Reily MD, NMR in drug design (2017) Archives of Biochemistry and Biophysics, 628, pp. 132-147.

 

  1. Han, J., Dzierlenga, A.L., Lu, Z., Billheimer, D.D., Torabzadeh, E., Lake, A.D., Li, H., Novak, P., Shipkova, P., Aranibar, N., Robertson, D., Reily, M.D., Lehman-Mckeeman, L.D., Cherrington, N.J. Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model (2017) Obesity, 25 (6), pp. 1069-1076

 

  1. Lewis AM, Croughan WD, Aranibar N, Lee AG, Warrack B, Abu-Absi NR, Patel R, Drew B, Borys MC, Reily MD, Li ZJ.  Understanding and controlling sialylation in a CHO Fc-Fusion process (2016) PLoS ONE, 11 (6), art. no. e0157111.

 

  1. Zheng JJ, Shields EE, Snow KJ, Nelson DM, Olah TV, Reily MD, Robertson DG, Shipkova PA, Stryker SA, Xin B, Drexler DM. The utility of stable isotope labeled (SIL) analogues in the bioanalysis of endogenous compounds by LC-MS applied to the study of bile acids in a metabolomics assay (2016) Analytical Biochemistry, 503, pp. 71-78.

 

  1. Reily MD, Tymiak AA, Metabolomics in the pharmaceutical industry (2015) Drug Discovery Today: Technologies, (2015), 25-31.

 

  1. Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ, Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease (2015) Amino Acids, 47(3), pp. 603-615.

 

  1. Khandelwal P, Stryker S, Chao H, Aranibar N, Lawrence RM, Madireddi M, Zhao W, Chen L, Reily MD, 1H NMR-based lipidomics of rodent fur: species-specific lipid profiles and SCD1 inhibitor-related dermal toxicity, J. Lipid Res. (2014) 55:(7) 1366-1374.

 

  1. Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ,  Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease (2014) Digestive Diseases and Sciences, 59 (2), pp. 365-374.

 

  1. Lake, A.D., Novak, P., Shipkova, P., Aranibar, N., Robertson, D., Reily, M.D., Lu, Z., Lehman-McKeeman, L.D., Cherrington, N.J.  Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease (2013) Toxicology and Applied Pharmacology, 268 (2), pp. 132-140.

 

  1. Robertson DG, Reily MD, The current status of metabolomics in drug discovery and development (2012) Drug Development Research, 73 (8), pp. 535-546.

 

  1. Benton HP, Want E, Keun HC, Amberg A, Plumb RS, Goldfain-Blanc F, Walther B, Reily MD, Lindon JC, Holmes E, Nicholson JK, Ebbels TMD, Intra- and interlaboratory reproducibility of ultra performance liquid chromatography-time-of-flight mass spectrometry for urinary metabolic profiling (2012) Analytical Chemistry, 84 (5), pp. 2424-2432.

 

  1. Robertson DG, Ruepp SU, Stryker SA, Hnatyshyn SY, Shipkova PA, Aranibar N, McNaney CA, Fiehn O, Reily, MD. Metabolomic and transcriptomic changes induced by overnight (16 h) fasting in male and female Sprague-Dawley rats (2011) Chemical Research in Toxicology, 24 (4), pp. 481-487.

 

  1. Robertson DG, Watkins PB, Reily, MD. Metabolomics in toxicology: Preclinical and clinical applications (2011) Toxicological Sciences, 120 (SUPPL.1), S146-S170.

 

  1. Aranibar N, Borys M, Mackin NA, Ly V, Abu-Absi N, Abu-Absi S, Niemitz M, Schilling B, Li ZJ, Brock B, Russell II RJ, Tymiak A, Reily MD, NMR-based metabolomics of mammalian cell and tissue cultures (2011) Journal of Biomolecular NMR, 49(3), 195-206.

 

  1. Aranibar N, Vassallo JD, Rathmacher J, Stryker, S, Zhang Y, Dai J, Janovitz EB , Robertson D, Reily M, Lowe-Krentz L, Lehman-McKeeman L.  Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling (2011) Analytical Biochemistry, 401(1), 84-91.

 

  1. Drexler DM, Reily MD, Shipkova PA.  Advances in mass spectrometry applied to pharmaceutical metabolomics (2011) Analytical and Bioanalytical Chemistry, 399 (8), 2645-2653.

 

  1. Qiu F, Zhang Y, Caceres-Cortes J, Reily MD Applications of vibrational circular dichroism for determining absolute confi guration in early drug discovery (2010) American Laboratory, 42 (10), 33-34.

 

  1. Caceres-Cortes, J., Reily, M.D. NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST. (2010) Bioanalysis, 2 (7), 1263-1276.

 

  1. Want EJ, Coen M, Masson P, Keun HC, Pearce JTM, Reily MD, Robertson DG, Rohde CM, Holmes E, Lindon JC, Plumb RS, Nicholson JK Ultra performance liquid chromatography-mass spectrometry profiling of bile acid metabolites in Biofluids: Application to experimental toxicology studies (2010) Analytical Chemistry, 82 (12), 5282-5289.

 

  1. Coen M, Want EC, Clayton TA, Rhode CM, Hong Y-S, Keun HC, Cantor GH, Metz AL, Robertson DG, Reily MD, Holmes EC, Lindon JC, Nicholson JK.  Mechanistic aspects and novel biomarkers of responder and non-responder phenotypes in galactosamine-induced hepatitis.  J Proteome Res (2009), 8(11), 5175-5187.

 

  1. Hong Y-S, Coen M, Rhode CM, Reily MD, Robertson DG, Holmes E, Lindon JC,  Nicholson JK.  Chemical shift calibration in 1H MAS NMR spectra of liver tissue samples exemplified using a study of glycine protection of galactosamine toxicity.  Magn Reson Chem (2009), 47 (SUPPL 1), S47-53.

 

  1. Warrack BM, Hnatyshyn S, Ott K-H, Reily MD, Sanders M, Zhang H, Drexler DM.  Normalization strategies for metabonomic analysis of urine samples.  J Chrom B (2009), 877(5-6), 547-552.

 

  1. Robosky LC, Wade K, Woolson D, Baker JD, Manning ML, Gage DA, Reily MD. Quantitative evaluation of sebum lipid components with nuclear magnetic resonance. J. Lipid Res. (2008), 49(3), 686-692.

 

  1. Robertson DG, Datta K, Wells D, Egnash L,  Robosky L, Manning M, Rohde C, Reily MD.  Metabonomic Evaluation of Metabolic Dysregulation in Rats Induced by PF 376304, a Novel Inhibitor of Phosphoinositide 3-Kinase.    Chem. Res. Tox. (2007),  20(12),  1871-1877.

 

  1. Coen M, Hong Y-S, Cloarec O, Rhode CM, Reily MD, Robertson DG, Holmes E, Lindon JC, Nicholson JK.  Heteronuclear 1H-31P Statistical Total Correlation NMR Spectroscopy of Intact Liver for Metabolic Biomarker Assignment: Application to Galactosamine-Induced Hepatotoxicity.    Anal. Chem. (Wash DC)  (2007),  79(23),  8956-8966.

 

  1. Rohde CM, Wells DF, Robosky LC, Manning ML, Clifford CB, Reily MD, Robertson DG.  Metabonomic evaluation of Schaedler altered microflora rats.    Chem. Res. Tox.   (2007), 20(12), 1871-1877.

 

  1. Walker GS, Atherton J, Bauman J, Kohl C, Lam W, Reily M, Lou Z, Mutlib A.  Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy.    Chem. Res. Tox.  (2007), 20(6), 876-886.

 

  1. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R,  Daykin CA, Fan TW-M, Fiehn O, Goodacre RO,  Griffin JL,  Hankemeier T,  Hardy N, Harnly J, Higashi R, Kopka J, Lane AN, Lindon JC, Marriott P, Nicholls AW, Reily MD, Thaden JJ, Viant MR.  Proposed minimum reporting standards for chemical analysis; chemical analysis working group (CAWG) metabolomics standards initiative (MSI).  Metabolomics (2007), 3, 211–221.

 

  1. Coen M, Hong YS, Clayton TA, Rohde CM, Pearce JT, Reily MD, Robertson DG, Holmes E, Lindon JC, and Nicholson JK.  The mechanism of galactosamine toxicity revisited; a metabonomic study.  J. Proteome Res., (2007), 6(7), 2711-2719.

 

  1. Schnackenberg LK, Dragan Y, Reily MD, Robertson DG, Beger RD.  Evaluation of NMR spectral data of urine in conjunction with measured clinical chemistry and histopathology parameters to assess the effects of liver and kidney toxicants.  Metabolomics (2007), 3(2), 87-100.

 

  1. Robosky LC, Reily MD, Avizonis D.  Improving NMR sensitivity by use of salt-tolerant cryogenically cooled probes.  Anal. Bioanal. Chem. (2007), 387(2), 529-532.

 

  1. Robertson DG, Reily MD, Baker JD.  Metabonomics in pharmaceutical discovery and development.    J. Proteome Res.  (2007), 6(2),  526-539.

 

  1. Quoted in: McGee P. Advancing NMR versatility.  Drug Discovery and Development (2006), 9(1), 26-30.

 

  1. Reily MD, Robosky LC, Manning ML, Butler A, Baker JD, and Winters RT.  DFTMP, an NMR reagent for assessing the near-neutral pH of biological samples. Journal of the American Chemical Society  (2006),  128(38),  12360-12361.

 

  1. Robosky, Lora C.; Wells, Dale F.; Egnash, Laura A.; Manning, Matthew L.; Reily, Michael D.; Robertson, Donald G.  Communication Regarding Metabonomic Identification of Two Distinct Phenotypes in Sprague-Dawley (Crl:CD(SD)) Rats.  Toxicological Sciences (2006),  91(1),  309.

 

  1. Robertson, Donald G.; Reily, Michael D.; Baker, J. David.  Metabonomics in preclinical drug development.    Expert Opinion on Drug Metabolism & Toxicology (2005), 1(3), 363-376.

 

  1. Zhang J, Herman EH, Robertson DG, Reily MD, Knapton A, Ratajczak HV, Rifai N, Honchel R, Blanchard KT, Stoll RE, Sistare FD, Mechanisms and Biomarkers of Cardiovascular Injury Induced by Phosphodiesterase Inhibitor III SK&F 95654 in the Spontaneously Hypertensive Rat.  Toxicologic Pathology, 34:152-163, 2006.

 

  1. Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Robertson DG,  Metabonomic Identification of Two Distinct Phenotypes in Sprague-Dawley (Crl:CD(SD)) Rats.    Toxicological Sciences  (2005),  87(1),  277-284.

 

  1. Lindon JC, Nicholson JK, Holmes E, Keun HC, Craig A, Pearce JTM, Bruce SJ, Hardy N, Sansone, S-A, Antti H, Jonsson P, Daykin C, Navarange M, Beger RD, Verheij ER, Amberg A, Baunsgaard D, Cantor GH, Lehman-McKeeman L, Earll M, Wold S, Johansson E, Haselden JN, Kramer K, Thomas C, Lindberg J, Schuppe-Koistinen I, Wilson, ID, Reily, MD, Robertson DG, Senn H, Krotzky A, Kochhar S, Powell J, van der Ouderaa F, Plumb R, Schaefer H, Spraul M.  Summary recommendations for standardization and reporting of metabolic analyses.    Nature Biotechnology  (2005),  23(7),  833-838.

 

  1. Kan H, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ, Woolf TF.  Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involved.    Drug Metabolism and Disposition  (2004), 32(6), 639-646. 

 

  1. Reily MD, Robertson DG, Delnomdedieu M, Baker JD.  High resolution NMR of biological fluids: metabonomics applications in pharmaceutical research and development.  American Pharmaceutical Review, 2003, 6(3), 105-109.

 

  1. Lindon JC, Nicholson JK, Holmes E, Antti H,  Bollard ME, Keun H, Beckonert O, Ebbels TM, Reily MD, Robertson D, Stevens GJ, Luke P, Breau AP, Cantor GH, Bible RH, Niederhauser U, Senn H, Schlotterbeck G, Sidelmann UG, Laursen SM, Tymiak A, Car BD, Lehman-McKeeman L, Colet, J-M, Loukaci A, Thomas C.  Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project.    Toxicology and Applied Pharmacology, 2003, 187(3), 137-146.

 

  1. Slim RM, Robertson DG, Albassam M, Reily MD, Robosky LC, Dethloff LA.  Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats.    Toxicology and Applied Pharmacology, 2002, 183, 108-116.

 

  1. Robosky LC, Robertson DF, Baker JD, Rane S, Reily MD.  In vivo toxicity screening programs using metabonomics.  Combin. Chem. High Throughput Screening, 2002, 5, 651-662.

 

  1. Annesley TM, Kurzyniec S, Nordblom GD, Buchanan N, Pool W, Reily M, Talaat R, and Roberts WL.  Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin. Clinical Chemistry, 2001, 47, 910-918.

 

  1. Robertson DG, Reily MD, Albassam M and Dethloff LA  Metabonomic assessment of vasculitis in rats, Cardiovascular Toxicology, 2001, 1, 7-19.

 

  1. Potts BCM, Deese AJ, Stevens GJ, Reily MD, Robertson DG, Theiss J, NMR of biofluids and pattern recognition: Assessing the impact of NMR parameters on the principal component analysis of urine from rat and mouse. J Pharmaceutical Biomed Anal, 2001, 26, 463-476.

 

  1. Robertson DG, Reily MD, Sigler REP P, Wells D, Patterson D and Braden T, Assessment of nuclear magnetic resonance (NMR) and pattern recognition technology ("metabonomics") for rapid in vivo screening of liver and kidney toxicants, Toxicol. Sci., 2000, 57, 326-337.

 

  1. Domagala JM., Gogliotti R, Sanchez JP., Stier MA., Musa K, Song Y, Loo J, Reily M, Tummino P, Harvey P, Hupe D, Sharmeen L, Mack D, Scholten J, Saunders J, Mcquade T.  2,2'-dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations.  Drug Des. Discovery 1997, 15, 49-61.

 

  1. Pool WF, Reily MD, Bjorge SM, Woolf TF,  Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans: species comparisons.  Drug Metab Dispos 1997, 25, 590-597.

 

  1. Cody WL, He JX, Reily MD, Haleen SJ, Walker DM, Reyner EL, Stewart BH and Doherty AM.  Design of potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DPhg16-Leu-Asp-Ile-[Nme]Ile-Trp21 (PD 156252):  Examination of its pharmacokinetic and spectral properties. J Med Chem 1997, 40,2228-2240.

 

  1. Loo JA, Holler TP, Sanchez J, Gogliotti R, Maloney L and Reily MD, Biophysical characterization of Zn ejection from HIV nucleocapsid protein by anti-HIV 2,2’dithiobisbenzamides and benzisothiazolones.  J Med Chem 1996, 39, 4313-4320.

 

  1. Pool WF, Woolf TF, Reily MD, Caprathe BW, Emmerling MR, Jaen JC, Identification of a 3-hydroxylated metabolite in rat and man:  metabolic profiling implications and pharmacology.  J. Med. Chem. (1996), 39(15), 3014‑3018.

 

  1. Omecinsky DO, Holub KE, Adams ME and Reily MD, Three-dimensional structure analysis of w-agatoxins:  Further evidence for common motifs among neurotoxins with diverse ion channel specificities. Biochemistry 1996, 35, 2836-2844.

 

  1. Leonard DM, Reily MD, Dunbar JB Jr, Holub KE, Cody WL, Hill KE, Welch KM, Flynn MA Reynolds EE and Doherty AM,  Structure-activity and biophysical studies of the C-terminal hexapeptide of endothelin. Bioorg Med Chem Lett 1995, 5, 967-972.

 

  1. Reily MD, Thanabal V, Adams ME, The Solution Structure of w-Aga-IVB, a P-type calcium channel antagonist from venom of the funnel web spider, Agelenopsis aperta, J Biol NMR 1995, 5, 122-132.

 

  1. Sefler A, He JX, Sawyer T, Holub KE, Omecinsky DO, Reily MD, Thanabal V, Akunne H, and Cody W.  Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues.  J Med Chem 1995, 38, 249-257.

 

  1. Reily MD, Holub KE, Gray WR, Norris TN and Adams ME.  Structure-activity relationships for p-type calcium channel selective w-agatoxins.  Nature Struct Biol 1994, 1, 853-856.

 

  1. Dotson GD, Nanjappan P, Reily MD, and Woodard RW, Stereochemistry of 3-deoxyoctulosonate 8-phosphate synthase. Biochemistry 1993, 32, 12392-12397.

 

  1. Thanabal V, Omecinsky  DO, Reily MD, and Cody WL, The 13C chemical shifts of amino acids in aqueous solution containing organic cosolvents:  application to the secondary structure characterization of peptides in aqueous trifluoroethanol solution. J Biomol NMR 1993, 4, 47-59.

 

  1. Adams ME, Mintz I, Reily MD, Thanabal V, Bean B, Structure and properties of w-aga-IVB, a new p-type calcium channel antagonist. Mol Pharmacol 1993, 44, 681-688.

 

  1. Radulovic L, Woolf T, Bjorge S, Taylor C, Reily M, Bockbrader H, Chang T.  Identification of a pyridinium metabolite in human urine following a single oral dose of 1-[2-[bis[4-(trifluoro-methyl)phenyl]methoxy]ethyl]-1,2,5,6,-tetrahydro-3-pyridinecarboxylic acid monohydrochloride, a-aminobutyric acid uptake inhibitor. Chem Res Toxicol 1993, 6, 341-344.

 

  1. Klutchko S, Hamby JM, Reily MD, Taylor MD, Hodges JC, Synthesis of 1,3-diols.  Ring opening of N-acyl activated lactams with carbon nucleophiles.  Synthetic Commun 1993, 23, 971-983.

 

  1. Hurley T, Colson C, Clipper SA, Uhlendorf SE, Reily MD, Photodecomposition of CI-981, an HMG-CoA reductase inhibitor.  Tetrahedron 1993, 49, 1979-1984.

 

  1. Doherty AM, Kornberg B, Reily MD, A study of the 3,3-sigmatropic rearrangement of chiral trichloroacetamidic esters, J Org Chem 1993, 58, 795-798.

 

  1. Hays SJ, Novak PM, Bigge CF, Colbry NL, Johnson G, Lescosky LJ, Malone TC, Michael A, Ortwine DF, Reily MD, Coughenour LL, Brahce LJ, Shillis JL, Probert A Jr, Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D-aspartate receptor, J Med Chem 1993, 36, 654-670.

 

  1. Reily MD, Thanabal V, Omecinsky DO, Structure-induced carbon-13 chemical shifts: a sensitive measure of transient localized secondary structure in peptides, J. Am. Chem. Soc 1992, 114, 6251-6252.

 

  1. Reily MD, Thanabal V, Lunney EA, Repine JT, Humblet CC, Wagner G, The design, synthesis, and solution structure of a renin Inhibitor.  Structural Constraints from NOE and homonuclear and heteronuclear coupling constants combined with distance geometry calculations.  FEBS Lett 1992, 302(1), 97-103.

 

  1. Reily MD, Thanabal V, Omecinsky DO, Dunbar JB Jr., Doherty AD, DePue PL, The solution structure of a cyclic endothelin antagonist, BQ-123, based on 1H-1H and 13C-1H three bond coupling constants.  FEBS Lett.1992, 300(2), 136-140.

 

  1. Cody WL, Giordani AB, Werness S, Reily MD, Bristol JA, Zhu GC, Dudley DT.  Analysis of rat amylin amide from commercial sources - identification of a mercury complex.  Bioorg Med Chem Lett 1991, 1(8), 415‑420.

 

  1. Beylin VG, Colbry NL, Giordani AB, Goel OP, Johnson DR, Leeds RL, Leja B, Lewis EP, Lustgarten DM, Showalter HDH, Sercel AD, Reily MD, Uhlendorf SE, Zisek KA, McDonnell P.  An improved synthesis of anticancer benzothiopyranoindazoles.  An efficient large-scale ß‑aminoethylation procedure [1].  J Heterocycl Chem 1991, 28, 517‑527.

 

  1. Reily MD, Dunbar JB, Jr.  The conformation of endothelin-1 in aqueous solution:  NMR-derived constraints combined and distance geometry and molecular dynamics calculations.  Biophys Biochem Res Comm 1991, 178(2), 570‑577.

 

  1. Marzilli LG, Mukundan S Jr, Xu J, Zon G, Bergman A, Yohannes P, Reily MD, Pt-DNA interactions:  oligonucleotide models,  In Platinum and other metal coordination compounds in cancer chemotherapy, Howell SB, ed, Plenum Press: New York, 1991, 101-114.

 

  1. Zehfus MH, Reily MD, Ulrich EL, Westler WM, Markley JL.  1H, 13C, and 15N resonance assignments for a ferrocytochrome C553 heme by multinuclear NMR spectroscopy.  Arch Biochem Biophys 1990, 276, 369‑373.

 

  1. Brennan ST, Colbry NL, Leeds RL, Leja B, Priebe SR, Reily MD, Showalter HDH, Uhlendorf S, Atwell GJ, Denny WA.  Anticancer anilinoacridines.  A process synthesis of the disubstituted amsacrine analog CI‑921.  J Heterocycl Chem 1989, 26, 1469‑1476.

 

  1. Stockman BJ, Reily MD, Westler WM, Ulrich EL, Markley JL.  Concerted two-dimensional NMR approaches to hydrogen‑1, carbon‑13, and nitrogen‑15 assignments in proteins.  Biochemistry 1989, 28, 230‑236.

 

  1. Reily MD, Hambley TW, Marzilli LG.  Macrochelate complexes of purine 5 ‑nucleotide triphosphates and monophosphates:  Definitive multinuclear NMR evidence supported by molecular modeling calculations.  J Am Chem Soc 1988, 110, 2999‑3007.

 

  1. Fouts CS, Reily MD, Marzilli LG, Zon GF.  31P NMR investigation of 14 self-complementary oligodeoxyribonucleotides (8‑mer to 14‑mer) treated with platinum complexes:  The downfield 31P NMR signal characteristic of anticancer drugs is observed only for molecules with adjacent G residues.  Inorg Chim Acta 1987, 137, 1‑13.

 

  1. Reily MD, Marzilli LG.  Novel, definitive NMR evidence for N7, ‑PO4 chelation of 6‑oxopurine nucleotide monophosphates to platinum anticancer drugs.  J Am Chem Soc 1986,108, 8299‑8300.

 

  1. Reily MD, Marzilli LG.  Anticancer Pt drug adducts with AMP:  Novel direct 1H and 195Pt NMR evidence for slowly interconverting "head-to-tail" rotamers.  Potential role of amine ligand bulk and NH groups in guanine selectivity and anticancer activity.  J Am Chem Soc 1986, 108, 6785‑6793.

 

  1. Marzilli LG, Hayden Y, Reily MD.  First definitive demonstration of ortho shielding effects on 195Pt NMR signals.  Dependence of shift on heterocyclic ligand basicity and ortho substituents in four series of complexes with chloro, dimethyl sulfoxide, and pyridine ligands.  Inorg Chem 1986, 25, 974‑978.

 

  1. Reily MD, Marzilli LG.  31P and 1H NMR spectroscopic studies of platinum adducts of PolyI PolyC.  The antitumor agent cis-Pt(NH3)Cl2 forms an N7,N7 bis-adduct.  J Am Chem Soc 1985, 107, 4916‑4924.

 

  1. Reily MD, Wilkowski K, Shinozuka K, Marzilli LG.  Nucleoside complexing.  Evidence for three metastable species in the reaction of nucleosides with cisDichlorobis(dimethyl sulfoxide)platinum(II).  Use of restricted rotation about Pt‑N bonds for structural assignments.  Inorg Chem 1985, 24, 37‑43.

 

  1. Marzilli LG, Reily MD, Heyl BL, McMurray CT, Wilson WD.  Evidence for similar structural changes on binding of platinum antitumor agents to DNA and nucleosomes.  FEBS Lett 1984,176, 389‑392.

 

 

 

 

 

 

 

 

Replace this text with information about you and your business or add information that will be useful for your customers.